Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
– TAK-003 is Being Evaluated for the Prevention of Dengue Disease Caused by Any Dengue Virus Serotype in Individuals 4 Years Through 60 Years of Age MUMBAI, NOVEMBER 23, 2022 (GPN)– Today announced that the…








